Thaller, Mark http://orcid.org/0000-0001-7772-2157
Homer, Victoria http://orcid.org/0000-0003-3639-7874
Hyder, Yousef
Yiangou, Andreas http://orcid.org/0000-0001-8905-5734
Liczkowski, Anthony
Fong, Anthony W. http://orcid.org/0000-0001-6285-0703
Virdee, Jasvir http://orcid.org/0000-0003-0679-9696
Piccus, Rachel
Roque, Marianne http://orcid.org/0000-0002-1406-5652
Mollan, Susan P. http://orcid.org/0000-0002-6314-4437
Sinclair, Alexandra J. http://orcid.org/0000-0003-2777-5132
Funding for this research was provided by:
Healthcare Quality Improvement Partnership
IIHUK registered patient charity
Association of British Neurologists and Guarantors of the Brain for a 3-year Clinical Research Training Fellowship
Medical Research Council (MR/KO15184/1)
National Institute of Health Research (NIHR-CS-011-028)
Sir Jules Thorn Charitable Trust
Article History
Received: 24 June 2022
Revised: 22 September 2022
Accepted: 23 September 2022
First Online: 15 October 2022
Declarations
:
: MT, VH, YH, AL, AF, JV, RP, MR report no conflicts. AY reports speaker fees for an educational talk from Teva, UK. SPM reports consultancy fees (Invex Therapeutics; Neurodiem); advisory board fees (Invex therapeutics; Janssen) and speaker fees (Heidelberg engineering; Chugai-Roche Ltd; Allergan; Santen; Chiesi; and Santhera). AJS reports personal fees from Invex therapeutics during the conduct of the study as well as share option and shareholdings, speaker fees (Novartis; Allergan; Teva UK) and consulting fees (Allergan; Chiesi; Novartis; Lundbeck).
: The study sponsor and funders had no role in the study design, interpretation of the data, data collection, or drafting of the manuscript.
: The study was ethically approved by National Health Service National Research Ethics Committee (14/LO/1208), IIH:LIFE study. The human study has been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.